Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q02643
UPID:
GHRHR_HUMAN
Alternative names:
Growth hormone-releasing factor receptor
Alternative UPACC:
Q02643; Q99863
Background:
The Growth hormone-releasing hormone receptor (GHRHR), encoded by the gene with accession number Q02643, plays a pivotal role in human growth processes. It acts as a receptor for GRF, coupling with G proteins to activate adenylyl cyclase, which in turn stimulates somatotroph cell growth, growth hormone gene transcription, and secretion.
Therapeutic significance:
GHRHR is directly implicated in Growth hormone deficiency, isolated, 4, a condition characterized by severe growth failure and short stature due to autosomal recessive deficiency of growth hormone. Understanding the role of GHRHR could open doors to potential therapeutic strategies, including growth hormone therapy which has shown positive responses in patients.